Efficacy and Safety of Agomelatine in Depressed Patients with Diabetes: A Systematic Review and Meta-Analysis
Adam Gędek, Szymon Modrzejewski, Michał Materna, Zofia Szular, Adam Wichniak, Paweł Mierzejewski, Monika Dominiak · 2024
Read Efficacy and Safety of Agomelatine in Depressed Patients with Diabetes: A Systematic Review and Meta-Analysis by Adam Gędek, Szymon Modrzejewski, Michał Materna, Zofia Szular, Adam Wichniak, Paweł Mierzejewski, Monika Dominiak (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641584.txt.
Description
Adam Gedek and co-authors present a 2024 review of a depression drug in patients who also have diabetes. Depression and diabetes are both common and often occur together. Each worsens the other, so care that helps both is prized. The drug, called agomelatine, is the focus. The team gathered studies under standard review rules. Eleven studies were found, spanning lab work and patient trials.
The drug shows strong promise for mood in this combined group, as the authors report. Anxiety gains appear as well. The review also probes how the drug may act in both diseases and what it does to sugar measures. Doctors who treat the common pair get a single summary instead of scattered papers. A drug that lifts mood without hurting sugar control fills a real gap. The authors still frame the proof as early, which suits a young literature.
Catalog record
| CREATOR | Adam Gędek, Szymon Modrzejewski, Michał Materna, Zofia Szular, Adam Wichniak, Paweł Mierzejewski, Monika Dominiak |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |